Evidence map›Paper›PMID 40770125›Full record

ArticleDermatology and therapy2025

Regenerative Skin Remodeling through Exosome-Based Therapy: A Case Study Demonstrating 21-Month Sustained Outcomes in Pore Size, Erythema, and Hyperpigmentation.

Young Seob Lee

Abstract read
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Plant Exosome Injection: A New Boost for Postlaser Vascular Repair.The Journal of clinical and aesthetic dermatology · 2026
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Young Seob LeeDepartment of Plastic Surgery, Chung-Ang University College of Medicine, Seoul, Korea. ylee2010@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVisible signs of skin aging, including enlarged pores, rosacea, and melasma, are often difficult to treat due to their multifactorial etiology. Most conventional therapies offer only temporary improvement and require ongoing maintenance. Exosome-based treatments present a regenerative approach that targets key biological dysfunctions associated with aging skin. CASE REPORT: A healthy female in her late 40s with Grade 3 pore enlargement, Subtype I rosacea, and epidermal-type melasma (MASI score 10) underwent two sessions of topical exosome application following superficial microneedling at 0.3 mm depth, performed on Day 1 and Day 21. Clinical progress was documented at baseline, 3 weeks, 5.5 months, and 21 months using standardized photography, AI-assisted 3D imaging, and validated scales (MASI, CEA, GAIS). Progressive, multidimensional improvements were observed: pore size reduced by up to 41%, erythema by 42%, and melanin deposition by 31% at 5.5 months. These effects were largely sustained at 21 months. Surface roughness metrics (Ra, Rq, Rmax, Rz, Rp, Rv) also improved significantly. DISCUSSION: The results indicate that topical exosome therapy combined with superficial microneedling promotes lasting improvements in key clinical markers of skin aging. The sustained effects over 21 months suggest biological remodeling rather than transient cosmetic correction. No adverse events occurred throughout the follow-up period, confirming the safety and tolerability of the protocol.

conclusionA short protocol of topical exosomes with superficial microneedling achieved durable improvements in pore size, redness, and pigmentation that persisted for nearly two years without retreatment. These findings support its potential as a low-risk, regenerative modality for long-term facial rejuvenation.

Indexed as

Exosome therapyFacial erythemaLong-term outcomesMelasmaPore reductionSkin rejuvenationSuperficial microneedling

Identifiers

PMID40770125
PMCPMC12454781

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.